Cancer treatment for people with RAD51C mutations
People with an inherited RAD51C mutation who have been diagnosed with cancer may have different treatment options than people without a mutation. To learn more about standard of care treatment options for specific types of cancer, visit our section on Cancer Treatment by Cancer Type.
If you have an inherited RAD51C mutation, have been diagnosed with cancer and any of the situations below apply to you, you may wish to speak to your doctor about your medical options. You may also consider enrolling in a clinical trial studying which treatments work best for people with an inherited RAD51C mutation.
PARP inhibitors are a type of targeted therapy that work by blocking a protein used to repair damaged DNA. They were initially developed to treat cancers in people with an inherited BRCA1 or BRCA2 mutation. Since then, research and additional FDA approvals have expanded use of PARP inhibitors to more situations. People with a RAD51C mutation who have been diagnosed with cancer may want to ask their doctor about PARP inhibitor therapy.
The PARP inhibitor, Lynparza (olaparib) has received FDA-approval to treat men with metastatic, castration-resistent prostate cancer, who have a mutation in RAD51C or another gene linked to a certain type of DNA damage repair. Lynparza may be used to treat men whose prostate cancer has progressed on enzalutamide (Xtandi) or abiraterone (Zytiga).
Several PARP inhibitors have been approved to treat ovarian cancers at different stages of the disease. In some situations, a tumor biomarker test known as an HRD test ("hemologous recombination deficiency") can help women with advanced ovarian cancer learn if they may benefit from a PARP inhibitor.
- Advanced cancer which has recurred after third-line treatment:
- HRD testing can help women with advanced ovarian cancer which has recurred after three lines of treatment learn if they may benefit from the PARP inhibitor Zejula (niraparib).
- Maintenance therapy after first-line treatment
- HRD testing can help women with advanced ovarian cancer learn if they may benefit from the PARP inhibitor Lynparza in combination with bevacizumab as maintenance therapy after first-line platinum chemotherapy.
- Zejula is approved for maintenance therapy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer who had a complete or partial response to first-line platinum-based chemotherapy. Zejula for maintenance therapy does not require an HRD test.
- Maintenance therapy after treatment of recurrent cancer
- Zejula, Rubraca (rucaparib) and Lynparza are all approved for maintenance therapy in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy. In this setting, none of these drugs requires an HRD test.
If you are a person with a RAD51C mutation, you can find peer support through the following resources:
- Register for the FORCE Message Boards to connect with others who share your situation. Once you register, you can post on the Share Your Mutation board to connect with other people who carry a RAD51C mutation and the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- FORCE's Peer Navigation Program will match you with a volunteer who shares your mutation and situation and provide you with a free resource guide.
- Contact the FORCE impact leaders in your area to link to local support groups and other resources.
- Attend a virtual support meeting in your area.
- Read the stories from members of our community.
The following cancer treatment studies are enrolling and may be of interest to people with a RAD51C mutation.
Advanced solid tumors of any type
- NCT04171700: A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR). This study is researching the PARP inhibitor rucaparib for patients with advanced solid tumors and with deleterious mutations in Homologous Recombination Repair genes, including RAD51C.
- NCT02286687: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in DNA Damage Repair Genes. This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in certain genes.
- NCT02401347: Talazoparib Beyond BRCA (TBB) Trial. People with an RAD51C mutation who have metastatic triple-negative breast cancer may qualify for this study. Talazoparib (Talzenna) is a type of treatment known as a PARP inhibitor, which is approved for metastatic breast cancer in people with a BRCA mutation. This study is looking at how well talazoparib works in people with other mutations.
- NCT04030559: Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects. This trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body.
NCT03395197: TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency. TALAPRO-2 is a study for men who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) which means that hormone therapies, one of the main treatment options for this type of cancer, have no effect and the tumor has spread to other parts of the body.
Visit our Research Search and Enroll Tool to find additional cancer treatment studies.